3,042 results match your criteria Cancer medicine[Journal]


Corrigendum.

Authors:

Cancer Med 2020 Jul 14;9(13):4876. Epub 2020 Jun 14.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3145DOI Listing

Corrigendum.

Authors:

Cancer Med 2020 Jul 18;9(13):4877. Epub 2020 Jun 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3234DOI Listing

Exosome-mediated delivery of miR-204-5p inhibits tumor growth and chemoresistance.

Cancer Med 2020 Jul 2. Epub 2020 Jul 2.

Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.

Background: Nano-sized extracellular vesicles secreted by cells play key roles in intercellular crosstalk, and appear to be an excellent biocompatible material as therapeutic cargoes in vivo. Previously, we have demonstrated that miR-204-5p is a key tumor suppressor that could inhibit tumor growth, metastasis and chemoresistance.

Methods: A HEK293T cell line stably expressing miR-204-5p (293T-miR-204) was constructed by lentivirus transduction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3248DOI Listing

Geriatric assessment domains to predict overall survival in older cancer patients: An analysis of functional status, comorbidities, and nutritional status as prognostic factors.

Cancer Med 2020 Jul 2. Epub 2020 Jul 2.

Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.

Cancer treatments for older patients must account for heterogeneity in health and functional status. Guidelines advocate the use of geriatric assessments (GAs), but comprehensive assessments are laborious and the utility of specific GA domains remains unclear. The identification of specific domains as prognostic factors may support survival predictions and treatment decisions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3205DOI Listing

A population-based study on the prognostic impact of primary tumor sidedness in patients with peritoneal metastases from colon cancer.

Cancer Med 2020 Jul 2. Epub 2020 Jul 2.

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Primary tumor location is an established prognostic factor in patients with (metastatic) colon cancer. Colon tumors can be divided into left-sided and right-sided tumors. The aim of this study was to determine the impact of primary tumor location on treatment and overall survival (OS) in patients with peritoneal metastases (PM) from colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3243DOI Listing

Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan.

Cancer Med 2020 Jul 1. Epub 2020 Jul 1.

Division of Health Services Research, National Cancer Center, Tokyo, Japan.

Background: The incidence of male breast cancer (MBC), although rare, has shown an increase. However, the current epidemiology of and practice patterns for MBC remain unclear. This study evaluated the characteristics and care patterns for MBC compared with female breast cancer (FBC) in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3267DOI Listing

Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.

Cancer Med 2020 Jul 1. Epub 2020 Jul 1.

Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Purpose: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti-CD19 and anti-CD20 CAR-T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3259DOI Listing

Breast cancer survivors' risk of interval cancers and false positive results in organized mammography screening.

Cancer Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Public Health Programmes, Regional Hospital Randers, Randers, Denmark.

Background: Breast cancer survivors are increasing followed for new breast cancers / recurrences by mammography screening only. We aimed at assessing how often breast cancer survivors get a false positive or false negative result at mammography screening.

Methods: All mammography screenings performed between 2007 and 2017 in the Danish national mammography screening programme were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3182DOI Listing

Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.

Cancer Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: In this study, we report the follow-up results of reduced dose of craniospinal radiotherapy (CSRT) followed by tandem high-dose chemotherapy (HDCT) in patients with high-risk medulloblastoma (MB).

Methods: Newly diagnosed high-risk MB patients (metastatic disease, postoperative residual tumor >1.5 cm , or large cell/anaplastic histology) over 3 years of age were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3199DOI Listing

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.

Cancer Med 2020 Jul 1. Epub 2020 Jul 1.

Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.

Background: Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late-stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five-drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in RRMM.

Methods: We retrospectively analyzed data of 56 patients with RRMM who received Pom-PAD-Dara between September 2016 and May 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3209DOI Listing

High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.

Cancer Med 2020 Jun 29. Epub 2020 Jun 29.

Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.

Background: High tumor mutation burden is shown to be associated with a poor clinical outcome. As the tumor-derived fraction of circulating cell-free DNA (cfDNA) is shown to reflect the genetic spectrum of the tumor, we examined whether the mutation burden of cfDNA could be used to predict the clinical outcomes of early-stage breast cancer (BC) patients.

Methods: We selected a set of 79 Finnish early-stage BC cases with a good prognosis based on traditional prognostic parameters but some of which still developed relapsed disease during follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3258DOI Listing

Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi-institutional study.

Cancer Med 2020 Jun 29. Epub 2020 Jun 29.

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Background: This study was conducted in order to develop a model for predicting response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC) using pretreatment quantitative ultrasound (QUS) radiomics.

Methods: This was a multicenter study involving four sites across North America, and appropriate approval was obtained from the individual ethics committees. Eighty-two patients with LABC were included for final analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3255DOI Listing

Clinical and cytopathological characteristics of HTLV-1 hodgkin lymphoma.

Cancer Med 2020 Jun 28. Epub 2020 Jun 28.

Division of Diagnostic Pathology, Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan.

Background: Human T-lymphotropic virus-1 (HTLV-1) Hodgkin lymphoma (HL) is difficult to differentiate from adult T-cell leukemia/lymphoma (ATLL) with HL-like histology (HL-like ATLL).

Methods: Cytological and immunohistological features, HTLV-1 proviral DNA integration, and rearrangements of the T-cell receptor (TCR) Cβ1 gene were examined in 11 HTLV-1 patients with HL-like disease.

Results: Six patients were classified as HTLV-1 HL and five as HL-like ATLL in accordance with genetic findings of HTLV-1 proviral DNA integration and rearrangements of the TCR Cβ1 gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3139DOI Listing

Assessment of somatic mutations in urine and plasma of Wilms tumor patients.

Cancer Med 2020 Jun 26. Epub 2020 Jun 26.

Laboratory of Genomics and Molecular Biology, International Research Center/CIPE, A. C. Camargo Cancer Center, São Paulo, Brazil.

Tumor DNA has been detected in body fluids of cancer patients. Somatic tumor mutations are being used as biomarkers in body fluids to monitor chemotherapy response as a minimally invasive tool. In this study, we evaluated the potential of tracking somatic mutations in free DNA of plasma and urine collected from Wilms tumor (WT) patients for monitoring treatment response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3236DOI Listing

Development and validation of an immune-related prognostic signature in lung adenocarcinoma.

Cancer Med 2020 Jun 26. Epub 2020 Jun 26.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, China.

Background: Lung adenocarcinomas (LUAD) is the most common histological subtype of lung cancers. Tumor immune microenvironment (TIME) is involved in tumorigeneses, progressions, and metastases. This study is aimed to develop a robust immune-related signature of LUAD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3240DOI Listing

External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end-of-life.

Cancer Med 2020 Jun 26. Epub 2020 Jun 26.

Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Background: The TEACHH and Chow models were developed to predict life expectancy (LE) in patients evaluated for palliative radiotherapy (PRT). We sought to validate the TEACHH and Chow models in patients who died within 90 days of PRT consultation.

Methods: A retrospective review was conducted on patients evaluated for PRT from 2017 to 2019 who died within 90 days of consultation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3257DOI Listing

Exosomes released from M2 macrophages transfer miR-221-3p contributed to EOC progression through targeting CDKN1B.

Cancer Med 2020 Jun 26. Epub 2020 Jun 26.

Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.

In contrast to other solid tumors within the abdominal cavity, epithelial ovarian cancers (EOCs) tend to undergo peritoneal metastasis. Thus, the peritoneal immune microenvironment is crucial for EOC progression. Previous reports indicate that the main immune cells within the peritoneum are M2 macrophages, specifically tumor-associated macrophages (TAMs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3252DOI Listing

Progesterone at high doses reduces the growth of U87 and A172 glioblastoma cells: Proteomic changes regarding metabolism and immunity.

Cancer Med 2020 Jun 26. Epub 2020 Jun 26.

Department of Neurosurgery, Acibadem Maslak Hospital and School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.

While pregnancy may accelerate glioblastoma multiforme (GBM) growth, parity and progesterone (P4) containing treatments (ie, hormone replacement therapy) reduce the risk of GBM development. In parallel, low and high doses of P4 exert stimulating and inhibitory actions on GBM growth, respectively. The mechanisms behind the high-dose P4-suppression of GBM growth is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3223DOI Listing

Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer.

Cancer Med 2020 Jun 26. Epub 2020 Jun 26.

Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

Background: Pretreatment clinical staging is essential to select therapy. However, there have been no published pretreatment gastric cancer nomograms constructed using pretreatment clinical prognostic factors, including in nonresection patients. We aimed to develop a new pretreatment gastric cancer nomogram for individualized prediction of overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3225DOI Listing

The effectiveness of chemotherapy for patients with pT3N0M0 renal pelvic urothelial carcinomas: An inverse probability of treatment weighting comparison using Surveillance, Epidemiology, and End Results data.

Cancer Med 2020 Jun 25. Epub 2020 Jun 25.

Department of Urology, Cancer Center, Sun Yat-sen University, Guangzhou, China.

Introduction: Unlike the established evidence to use chemotherapy for urothelial carcinoma of the bladder, presently there are insufficient data to inform a recommendation on upper urinary tract urothelial carcinoma treatment. The prognosis for patients with stage T4 and positive lymph nodes is poor; however, primary tumors in the renal pelvis are associated with favorable prognoses compared to those located in the ureter. Our study aimed at investigating the effectiveness of chemotherapy in patients with pT3N0M0 renal pelvic urothelial carcinomas (RPUC) who have relative favorable prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3238DOI Listing

Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.

Cancer Med 2020 Jun 25. Epub 2020 Jun 25.

Service of Endocrinology, University Hospital 12 de Octubre, Madrid, Spain.

Background: Conflicting results has been reported regard osteoporosis and fractures in patients with Differentiated Thyroid Cancer (DTC). Our objective was to evaluate the long-term effects of TSH suppression therapy with Levothyroxine (LT4) on trabecular bone score (TBS) and bone mineral density (BMD) in females with DTC after thyroidectomy.

Methods: About 145 women with resected DTC and receiving long-term TSH therapy, were stratified according to the degree of TSH suppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3200DOI Listing

Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma.

Cancer Med 2020 Jun 24. Epub 2020 Jun 24.

Department of Pediatrics, Futian Women and Children Health Institute, Shenzhen, People's Republic of China.

Uridine phosphorylase 1 (UPP1) has been reported as an oncogene in several malignancies. In glioma, the role of UPP1 remains unclear. This study was performed to explore its role in glioma at transcriptional level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3251DOI Listing

The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.

Cancer Med 2020 Jun 24. Epub 2020 Jun 24.

Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Objectives: Exploring the efficacy and safety of perioperative chemotherapy on patients with AGC at different clinical and pathological stages.

Methods: A phase III randomized, multicenter, trial comparing adjuvant (arm A) or perioperative S-1 plus oxaliplatin (SOX, arm B), and perioperative capecitabine plus oxaliplatin (XELOX, arm C) was initiated in T3/4, node + gastric cancer patients (unclear). Each patient received an 8-cycle chemotherapy (3 weeks for one cycle). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3224DOI Listing

Wound healing after excision of subcutaneous tumors treated with near-infrared photoimmunotherapy.

Cancer Med 2020 Jun 24. Epub 2020 Jun 24.

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy that employs a combination of infrared light and tumor-targeted monoclonal antibody-photoabsorber conjugates to cause both direct tumor necrosis and immunogenic cell death. NIR-PIT may have potential in the perioperative setting before surgery, and therefore it is important to know the effect of NIR-PIT on wound healing. Fifty mice were implanted with subcutaneous xenografts of N87 human gastric cancer cells, and tumors were excised after reaching a predetermined size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3247DOI Listing

Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.

Cancer Med 2020 Jun 24. Epub 2020 Jun 24.

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Prior studies of conventional chemotherapy or epidermal growth factor receptor inhibitors for advanced (ie, locally advanced cutaneous squamous cell carcinoma [laCSCC] or metastatic [mCSCC]) cutaneous squamous cell cancer enrolled ≤ 40 patients. This retrospective, observational study assessed real-world treatment patterns and clinical outcomes in patients with unresectable laCSCC or mCSCC using electronic health records of patients who initiated first-line (1L) systemic treatment from 1 January 2008 to 31 December 2015, with follow-up to 30 September 2017. The median duration of follow-up from 1L treatment was 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3146DOI Listing

Sex differences in solid pseudopapillary neoplasm of the pancreas: A population-based study.

Cancer Med 2020 Jun 23. Epub 2020 Jun 23.

Department of Pancreatobiliary Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

Objective: Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare tumor. This study aims to examine the clinicopathological features and surgical treatments of SPN and compare the clinical behavior and prognosis between men and women with SPN.

Methods: We collected the population data of patients with SPN diagnosed between 2004 and 2017 from the SEER database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3180DOI Listing

Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma.

Cancer Med 2020 Jun 23. Epub 2020 Jun 23.

Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.

Background: Racial/ethnic differences in mortality have not been well studied for either non-cardia gastric cancer (NCGC) or cardia gastric cancer (CGC). The aim of this study was to examine the US mortality rates for these cancer subtypes, as well as esophageal adenocarcinoma (EAC) as a comparator.

Methods: We identified 14 164 individuals who died from NCGC, 5235 from CGC, and 13 982 from EAC in the Surveillance, Epidemiology, and End Results database between 2004 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3063DOI Listing

Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness.

Cancer Med 2020 Jun 23. Epub 2020 Jun 23.

Faculty of Medicine, Biochemistry Department, Umm Al-Qura University, Makkah, Saudi Arabia.

Background: Prostate cancer (PCa) is one of the most frequently diagnosed cancers worldwide. Despite the growing evidence associating obesity and adipokines, particularly leptin and its receptors, with cancer development and progression, it is still a debatable matter in PCa.

Objectives: We aimed to assess the role of leptin and its receptors as potential biomarkers for the risk of PCa development and aggressiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3082DOI Listing

Mechanisms of Epstein-Barr virus nuclear antigen 1 favor Tregs accumulation in nasopharyngeal carcinoma.

Cancer Med 2020 Jun 22. Epub 2020 Jun 22.

Department of Otolaryngology, Head and Neck Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background: Documented reports proved that Epstein-Barr virus (EBV) infection increased infiltration of Tregs in malignancy. However, the mechanism of EBV recruitment Tregs into nasopharyngeal carcinoma (NPC) tissues has not been detailed discussion.

Methods: Expression of EBV nuclear antigen 1 (EBNA1) and Foxp3 in NPC tissue samples was detected by immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3213DOI Listing

Discordance between pediatric self-report and parent proxy-report symptom scores and creation of a dyad symptom screening tool (co-SSPedi).

Cancer Med 2020 Jun 21. Epub 2020 Jun 21.

Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada.

Symptom Screening in Pediatrics Tool (SSPedi) (age 8-18 years) and mini-SSPedi (age 4-7 years) can be used to self-report and proxy-report bothersome symptoms in pediatric patients receiving cancer treatments. There are limitations of sole child self-report or proxy-report. An approach in which children and parents complete symptom reports together may be useful. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3235DOI Listing

AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer.

Cancer Med 2020 Jun 20. Epub 2020 Jun 20.

Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.

Background: To investigate the effect of serum aspartate transaminase/alanine transaminase (AST/ALT) on the risk of prostate cancer.

Methods: A total of 404 patients undergoing prostate biopsy from April 2016 to July 2019 were enrolled. One hundred and ninety-four patients with prostatic cancer (PCa) were diagnosed by pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3086DOI Listing

Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.

Cancer Med 2020 Jun 18. Epub 2020 Jun 18.

Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.

Background: Peripheral T-cell lymphoma (PTCL) represents a heterogeneous and rare subgroup of aggressive lymphomas that generally demonstrate poor clinical outcomes with conventional treatment. Since the prognosis of PTCL is heterogeneous, more accurate risk assessment, and risk-adapted treatment strategies are required. In this study, we examined whether interim positron emission tomography (iPET)-computed tomography (PET/CT) results can be combined with baseline volume-based metabolic assessments including total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) for risk stratification in PTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3226DOI Listing

Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?

Cancer Med 2020 Jun 18. Epub 2020 Jun 18.

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Background: Population-based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B-cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data (especially at the population level) that show a similar trend in OS improvement, in the most recent time period. We hypothesized that survival for DLBCL patients diagnosed in the United States has continued to improve in recent years and intended to measure outcome improvements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3237DOI Listing

Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis.

Cancer Med 2020 Jun 18. Epub 2020 Jun 18.

Department of Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.

LncRNAs play crucial roles in the development of various cancers including hepatocellular carcinoma (HCC). Nevertheless, the function of the long noncoding RNA (lncRNA) FOXD2-AS1 in HCC is still poorly understood. In this study, we focused on the role of FOXD2-AS1 in HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3204DOI Listing

Cardiovascular disease and asymptomatic childhood cancer survivors: Current clinical practice.

Cancer Med 2020 Jun 18. Epub 2020 Jun 18.

Department of Pediatrics, Division of Pediatric Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: It is poorly understood how cardiovascular screening in asymptomatic childhood cancer survivors (CCS) is applied to and impacts clinical care.

Objectives: To describe the current role of cardiovascular screening in the clinical care of asymptomatic CCS.

Methods: At 50 pediatric academic medical centers, a childhood cancer survivorship clinic director, pediatric cardiologist, and adult cardiologist with a focus on CCS were identified and invited to participate in a survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3190DOI Listing

miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.

Cancer Med 2020 Jun 16. Epub 2020 Jun 16.

Division of Molecular Medicine, St. John's Research Institute, Bangalore, India.

Despite the established benefits of long-term endocrine therapy, women with hormone receptor-positive breast cancer remain at risk for late relapse. The basis of this is multi-factorial including genetic, epigenetic, and host factors. In this study we have explored the epigenetic regulation of estrogen receptor (ER)-dependent molecular and cellular phenotype by hsa-miR-18a-5p using well-established human ER-positive (ER+) breast cancer cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3183DOI Listing

A nomogram for prediction of stage III/IV gastric cancer outcome after surgery: A multicenter population-based study.

Cancer Med 2020 Jun 15. Epub 2020 Jun 15.

Department of Epidemiology and Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.

Most patients with gastric cancer (GC) are first diagnosed at stage III-IV and surgery resection remains the primary therapeutic modality for these patients. However, clinical staging used for prediction of those patients provides limited information. We collected clinicopathological data and disease-progression information from 508 patients with stage III-IV GC at three Chinese hospitals and 1298 patients from the Surveillance, Epidemiology, and End Results database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3215DOI Listing

The clinical application value of mixed-reality-assisted surgical navigation for laparoscopic nephrectomy.

Cancer Med 2020 Jun 15. Epub 2020 Jun 15.

Department of Radiology, Jinling Hospital, Nanjing Medical University, Nanjing, China.

Purpose: Laparoscopic nephrectomy (LN) has become the preferred method for renal cell carcinoma (RCC). Adequate preoperative assessment or intraoperative navigation is key to the successful implementation of LN. The aim of this study was to evaluate the clinical application value of mixed-reality-assisted surgical navigation (MRASN) in LN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3189DOI Listing

Serum uric acid levels and risk of kidney cancer incidence and mortality: A prospective cohort study.

Cancer Med 2020 Jun 14. Epub 2020 Jun 14.

Clinical Research Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China.

Objective: Epidemiological evidence investigating serum uric acid and kidney cancer risk remains unclear. We conducted this study to examine the relationship between serum uric acid and the incidence and mortality of kidney cancer.

Methods: This is a prospective analysis of 444 462 participants without any cancer from the UK Biobank. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3214DOI Listing

External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.

Cancer Med 2020 Jun 14. Epub 2020 Jun 14.

Division of Clinical Oncology, Department of Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, Graz, Austria.

Background: The advanced lung cancer inflammation index (ALI) was first introduced for prognosis prediction in lung cancer patients and since then evaluated in several other malignancies. However, in pancreatic cancer (PC) the ALI and its prognostic utility were only investigated in a comparably small and specific cohort of locally advanced PC patients treated with chemoradiotherapy.

Methods: In our single-center cohort study, we included 429 patients with histologically verified PC who were treated between 2003 and 2015 at our academic institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3233DOI Listing

Differences in the preferential location and invasiveness of diffuse low-grade gliomas and their impact on outcome.

Cancer Med 2020 Jun 14. Epub 2020 Jun 14.

Department of Neuroscience, Neurosurgery, Uppsala University, Uppsala, Sweden.

Background: Low-grade gliomas (LGGs) are primary diffuse slow-growing brain tumors derived from glial cells. The management of these tumors is dependent on their location, which often harbors eloquent areas. We retrospectively recorded the location of diffuse gliomas to identify whether specific differences exist between the histological types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3216DOI Listing

Breast cancer supplemental screening: Women's knowledge and utilization in the era of dense breast legislation.

Cancer Med 2020 Jun 14. Epub 2020 Jun 14.

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, USA.

Background: Given the growth in dense breast notification (DBN) legislation in the United States, we examined the association between different types of DBN laws and supplemental screening behaviors among women.

Methods: We surveyed in March-April 2018 a nationally representative sample of women aged 40-59 years who received a routine screening mammogram in the past 18 months. Survey items included the following topics regarding supplemental screening: discussing risks or benefits with a provider, knowledge about the risk of false positives, and utilization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3218DOI Listing

Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma.

Cancer Med 2020 Jun 14. Epub 2020 Jun 14.

Department of Gastroenterology, Ajou University School of Medicine, Suwon, South Korea.

Currently, a reliable serum biomarker for hepatocellular carcinoma (HCC) has not been established, particularly for early-stage HCC (single tumor < 2 cm). We aimed to investigate diagnostic serum exosomal microRNA (exo-miR) panel for early-stage HCC. Driver oncogenic miR (onco-miR) candidates were selected by integrative analysis of miR expression profiles from three different RNA sequencing datasets of human HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3230DOI Listing

Development of a prediction model with serum tumor markers to assess tumor metastasis in lung cancer.

Cancer Med 2020 Jun 14. Epub 2020 Jun 14.

Department of Clinical laboratory, Dazhou Central Hospital, Dazhou, Sichuan, China.

Background: This study aimed to explore the possibility of serum tumor markers (TMs) combinations in assessing tumor metastasis in patients with lung cancer.

Methods: We performed a retrospective analysis of 541 patients diagnosed with lung cancer between January 2016 and December 2017 at the Pneumology Department of Dazhou Central Hospital. Serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA153, CA199, CA724, cytokeratin 19 fragment (CYFRA), and neuron-specific enolase (NSE) levels were quantified in each patient at the time of lung cancer diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3184DOI Listing

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.

Cancer Med 2020 Jun 11. Epub 2020 Jun 11.

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.

Background: Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose intensity affect survival.

Methods: Patients treated with sorafenib for HCC from January 2008 to July 2016 in several Canadian provinces were included and retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3228DOI Listing

Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer.

Cancer Med 2020 Jun 11. Epub 2020 Jun 11.

Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa City, Japan.

Background: Immunotherapy for cancer patients has been the subject of attention in recent years. In this study, we investigated whether αβT-cell therapy causes changes in the host's immune cell profile, and if so, the effect of these changes on prognosis.

Methods: Peripheral blood mononuclear cells (PBMCs) from 30 gastric cancer patients who had completed one course of αβT-cell therapy were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3152DOI Listing

Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis.

Cancer Med 2020 Jun 11. Epub 2020 Jun 11.

Department of Urology, Institute of Urology, National Clinical Research Center for Geriatrics and Center of Biomedical Big Data, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.

Purpose: To study prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma (MPUC) of the urinary bladder.

Method: We used the national Surveillance, Epidemiology, and End Results database (2004-2016) to compare MPUC with transitional cell carcinoma (TCC) and to investigate prognostic values of clinicopathological characteristics, as well as survival outcomes, in MPUC of the urinary bladder. A multivariable Cox proportional hazard model, subgroup analyses, and propensity score matching were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3147DOI Listing

Efficacy and safety of carbon-ion radiotherapy for the malignant melanoma: A systematic review.

Cancer Med 2020 Jun 10. Epub 2020 Jun 10.

The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.

Malignant melanomas (MMs) were the fifth most common cancer in men and the sixth most common cancer in women in 2018, respectively. These are characterized by high metastatic rates and poor prognoses. We systematically reviewed safety and efficacy of carbon-ion radiotherapy (CIRT) for treating MMs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3134DOI Listing

Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways.

Cancer Med 2020 Jun 10. Epub 2020 Jun 10.

Value-based Programs, US Oncology/McKesson Specialty Health, Texas Oncology, Dallas, TX, USA.

The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value-based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value-based cancer care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3193DOI Listing

Health-related quality of life in long-term prostate cancer survivors after nerve-sparing and non-nerve-sparing radical prostatectomy-Results from the multiregional PROCAS study.

Cancer Med 2020 Jun 10. Epub 2020 Jun 10.

National Institute for Cancer Epidemiology and Registration (NICER), c/o University of Zurich, Zurich, Switzerland.

Background: Nerve-sparing (NS) surgery was developed to improve postoperative sexual and potentially urological outcomes after radical prostatectomy (RP). However, it is largely unknown how NSRP affects health-related quality of life (HRQoL) including urinary and sexual outcomes in prostate cancer (PC) survivors 5-10 years after diagnosis in comparison with Non-NSRP.

Methods: The study population included 382 stage pT2-T3N0M0 PC survivors 5-10 years post diagnosis, who were identified from the multiregional Prostate Cancer Survivorship in Switzerland (PROCAS) study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3197DOI Listing